Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Net Margin (2016 - 2024)

Mimedx's Net Margin history spans 15 years, with the latest figure at 12.86% for Q4 2025.

  • For Q4 2025, Net Margin rose 486.0% year-over-year to 12.86%; the TTM value through Dec 2025 reached 3.63%, down 841.0%, while the annual FY2025 figure was 11.6%, 43.0% down from the prior year.
  • Net Margin for Q4 2025 was 12.86% at Mimedx, up from 8.01% in the prior quarter.
  • Across five years, Net Margin topped out at 51.63% in Q4 2023 and bottomed at 20.5% in Q1 2022.
  • The 5-year median for Net Margin is 8.01% (2024), against an average of 3.07%.
  • The largest annual shift saw Net Margin soared 7464bps in 2021 before it plummeted -4362bps in 2024.
  • A 5-year view of Net Margin shows it stood at 2.75% in 2021, then surged by 498bps to 10.94% in 2022, then surged by 372bps to 51.63% in 2023, then tumbled by -84bps to 8.01% in 2024, then soared by 61bps to 12.86% in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Net Margin are 12.86% (Q4 2025), 8.01% (Q4 2024), and 9.37% (Q3 2024).